Basic Disinfection Practices for Tissue Culture Laboratories

Marian Downing
This one-hour webinar will discuss basic practices for combating contamination in tissue culture laboratories. It will include a review of common laboratory contamination sources as well as how to choose and use an appropriate disinfectant. Basic clean laboratory practices as they apply to tissue culture activities will be discussed. The use and cleaning of biosafety cabinets and incubators and the use of appropriate personal protective equipment will be covered. A basic checklist for investigating contamination issues will also be provided. This webinar will be interactive, and the audience will have the ability to ask questions, as time allows.

This course has been pre-approved for 0.125 ABSA Certification Maintenance Points.
Feb 2 2012
76 mins
Basic Disinfection Practices for Tissue Culture Laboratories
More from this community:

Health IT

Webinars and videos

  • Live and recorded (700)
  • Upcoming (18)
  • Date
  • Rating
  • Views
  • Malware today is very different from just a few years ago. Traditional AV technology is no longer able to consistently and fully remediate or defend against today’s most advanced threats. New and emerging threats such as ransomware, social engineering driven attacks and micro variant financial threats are just some examples of difficult to remediate infections. This presentation will take a look at the malware landscape and explain why these tactics are so effective against traditional AV technology. We will examine three specific families of infections and highlight their tactics to evade detection and what issues occur with remediation. Lastly, we will talk about Webroot’s innovation and how our SecureAnywhere AV solution is capable of defending against, and remediating today’s most advanced threats.
  • Today’s Health IT leaders face a difficult task in handling mobile device security and policy compliance, particularly given the mobile transformation happening in healthcare today. Driven in part by the adoption of new care models like remote patient monitoring and telemedicine, and the Bring Your Own Device, or BYOD trend, the consumerization of IT is driving end-user demand for ubiquitous access – to networks, to clouds, to applications, to everything – from any device, anywhere at any time.

    In this webinar, we will highlight the challenges of mobile device security, management and policy today. We will consider the issues faced by Health IT teams when managing different operating systems across a myriad of devices, some of which are user-owned. Finally we’ll look at how Juniper Networks solutions address a broad spectrum of security and end-user experience issues, as we walk through a day in the life of a mobile clinician. Register now to attend!
  • Did you know that the majority of all web attacks occur at the website or web application layer? Can you see attackers threatening your public web applications right now?

    Join Juniper security experts, Pete McMullen & Ben Griffin for a 60 minute Junos WebApp Secure (JWAS) and Spotlight Secure overview and LIVE DEMO to learn how Juniper can protect your web assets from the largest Internet security threats known!
  • Forty-four states, DC and four territories have adopted the Common Core State Standards (CCSS). This means that school districts across the country are planning for 100% online assessments during the 2014-2015 school year. One of the most important conditions needed for being able to administer online assessments is network infrastructure readiness.
    Attend this 30-minute webinar and join Gavin Lee, Senior K-12 Business Development Manager at Juniper Networks, to discuss the critical network must-haves that all school districts should consider when looking to deploy a robust and supportable network. You will also receive practical guidance on how to get the most out of your network infrastructure and how to best prepare for the CCCSS assessments:
    • Consortia network infrastructure
    • Wired and wireless network capabilities
    • Robust network security
    • Network support readiness
    • Juniper Networks network infrastructure readiness resources
  • Heartbleed is not an exploit you want to ignore as an IT professional. It exposes passwords and cryptographic keys, and requires not only that you patch OpenSSL for each of the services using the OpenSSL library, but also that you replace the private keys and certificates so that attackers won’t be able to use any of the data compromised by the vulnerability. The simplicity of the exploit makes it powerful. It appears that over a half million websites are vulnerable.
    In this session we'll cover:
    What you need to know about the Heartbleed vulvnerability
    How to detect it using AlienVault USM
    How to investigate successful Heartbleed exploits
  • SharePoint 2013 features a new app model that allows you create easy-to-use, lightweight web applications that integrate popular web standards and technologies to extend the capabilities of a SharePoint website. Join our live webcast for an overview of Microsoft’s new SharePoint app model and learn:

    • How to configure app development for SharePoint on-premises
    • How developers can kick-start app development using SharePoint Online
    • What the differences are between provider-hosted and autohosted apps for SharePoint
  • As most IT Pros are aware, as of April 8th, 2014, Microsoft will stop releasing security patches for Windows XP. Unfortunately, most folks will not be able to migrate all Windows XP machines by that deadline. How will you limit the security risks posed by these now vulnerable assets? Join us for this webinar outlining practical strategies to help you cover your assets.
    In this session we'll cover:
    The primary attack vectors you need to consider
    Immediate actions you can take to limit the exposure of your XP assets
    Warning signs to watch out for that could signal an attack
    How to closely monitor your vulnerable assets with AlienVault USM
  • Join this unique roundtable chat with three InfoSec Professionals who have recently climbed the BYOD mountain and come back down to share their stories. We’ll discuss the industry and regulatory differences, managing user expectations of privacy, legal implications and technical pitfalls in this 60 minute Security Leadership Series webinar, brought to you on April 10, 2014 at 1PM Eastern in partnership with Capella University.
  • Virtual Desktop Infrastructure (VDI) is now a mature technology that is being adopted by organizations with increasing popularity. However, the user community who needs high-end graphics capabilities in their work (such as 3D modelling and simulations) were somewhat skeptical about the capabilities and performance of VDI with applications using 3D graphics, compared to the performance they can expect from a physical PC or workstation with a dedicated GPU. Recent advances in VDI help make this performance gap narrower by providing the capabilities for either a pool of virtual desktops (shared GPU) or, to a specific virtual desktop (GPU pass through), depending on the user requirements.

    Join Teradici for a deep dive on Graphics Processing Unit (GPU) deployment options for VMware Horizon View and walk away with the GPU knowledge to increase productivity and accelerate your application performance in your virtual environment. In this webinar, we will discuss GPU technology related to Virtual Shared Graphics Acceleration (vSGA),Virtual Dedicated Graphics Acceleration (vDGA) and Teradici PCoIP Hardware Accelerator deployment options available today. We will also explore how using PCoIP Hardware Accelerator in combination with a GPU allows you to expand and enhance your VDI deployment to provide a rich and interactive graphical experience across a broad set of use cases and ensure application performance.

    Key Takeaways
    • Understand the graphics acceleration options for VMware Horizon View
    • Learn how PCoIP Hardware Accelerator complements GPU implementations to improve 3D application performance
  • Virtual Desktop Infrastructure (VDI) is now a mature technology that is being adopted by organizations with increasing popularity. However, the user community who needs high-end graphics capabilities in their work (such as 3D modelling and simulations) were somewhat skeptical about the capabilities and performance of VDI with applications using 3D graphics, compared to the performance they can expect from a physical PC or workstation with a dedicated GPU. Recent advances in VDI help make this performance gap narrower by providing the capabilities for either a pool of virtual desktops (shared GPU) or, to a specific virtual desktop (GPU pass through), depending on the user requirements.

    Join Teradici for a deep dive on Graphics Processing Unit (GPU) deployment options for VMware Horizon View and walk away with the GPU knowledge to increase productivity and accelerate your application performance in your virtual environment. In this webinar, we will discuss GPU technology related to Virtual Shared Graphics Acceleration (vSGA),Virtual Dedicated Graphics Acceleration (vDGA) and Teradici PCoIP Hardware Accelerator deployment options available today. We will also explore how using PCoIP Hardware Accelerator in combination with a GPU allows you to expand and enhance your VDI deployment to provide a rich and interactive graphical experience across a broad set of use cases and ensure application performance.

    Key Takeaways
    • Understand the graphics acceleration options for VMware Horizon View
    • Learn how PCoIP Hardware Accelerator complements GPU implementations to improve 3D application performance
  • Channel
  • Channel profile
Up Down
  • Animal-free, Synthetic Surfaces for Cell Types Relevant in Clinical Research Apr 24 2014 4:00 pm UTC 60 mins
    Expansion of stem cells and some primary cells requires either animal-origin components in culture media or coating of the culture vessels with human or animal-derived extracellular matrix (ECM) protein. Growing concerns about introducing human and animal-derived pathogens into the culture necessitate the need for animal- free (xeno-free and human-origin components-free) culture environment. Herein, we present defined and synthetic surfaces for cell culture. Corning® PureCoat™ ECM Mimetic cultureware collagen I peptide and fibronectin peptide support culture of cell types requiring collagen I or fibronectin protein -coated surfaces. Corning Synthemax® surface consists of a vitronectin peptide and supports undifferentiated expansion of human pluripotent stem cells (hPSC) and neural progenitor cells (NPCs). ECM Mimetic and Synthemax cultureware are pre-coated, synthetic, animal-free, and room temperature stable. Synthemax-SC is available for self-coating.

    We demonstrate expansion and functionality of several clinically relevant cell types including hPSCs, mesenchymal stem cells (MSCs), human keratinocytes (HKN), endothelial colony forming cells (ECFCs), NPCs and cell lines for biomanufacturing (CHO and Vero) on these surfaces. Corning Synthemax and ECM Mimetic cultureware are versatile surfaces compatible with multiple media for culture of various cell types providing a ready to use alternative to ECM protein coating where animal-free and defined conditions are desirable.
  • Corning TransportoCells™, A Novel “Thaw and Go” Cell-based Transporter Model Recorded: Mar 31 2014 54 mins
    SLC transporter-mediated drug–drug interactions (DDI) can significantly impact the pharmacokinetics and safety profiles of drugs. The regulatory agencies (FDA/EMA) recent guidance documents recommend testing six SLC transporters for potential DDI: OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT2. The 2013 drug transporter white paper published by the International Transporter Consortium (ITC) identified additional drug transporters relevant to drug development, including the Multidrug and Toxin Extrusion SLC transporters: MATE1 and MATE2-K. The webinar will introduce a novel cell-based SLC transporter model system - the recently launched “Corning™ TransportoCells™” - for studying regulatory agency recommended SLC transporters. The new system provides a convenient “thaw and go”, high performing mammalian cell model which supports regulatory agency recommendations for evaluating transporter mediated drug-drug interactions in vitro. In this webinar, we will provide an overview of the product validation and applications for the TransportoCells™ transporter model system. Validation data will also be presented for the newly available MATE1 and MATE2-K Corning™ TransportoCells™.
  • Materials and Systems for Optimizing 3D Cell Culture Environments Recorded: Feb 18 2014 64 mins
    Three-dimensional (3D) cell culture environments provide structural and biochemical cues for cellular differentiation and functionality. For specialized cell types such as primary cells, a two-dimensional growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, signal transduction, and tissue-specific gene expression. This webinar will highlight applications that rely on 3D materials and systems, including Corning ® Matrigel® Matrix (reconstituted basement membrane), Collagen Type I, Corning PuraMatrix™ Peptide Hydrogel, and permeable supports (cell culture inserts). To demonstrate the effectiveness of these environments, the biological and functional properties of a variety of cell types will be discussed.
  • Development of Hydrogel-Based 3D Cancer Stem Cell & Tumorsphere Models for HTS Recorded: Dec 3 2013 48 mins
    Cancer stem cells (CSCs), commonly referred to as tumor initiating cells (TICs), are thought to be the origin of replicating malignant cells that remain after the primary tumor is removed or eradicated. While the contribution of TICs to cancers of hematopoietic origin is well established, there is a growing body of evidence that supports the presence of TICs within solid tumors. This heterogeneity contributes to the intrinsic resistance of solid tumors to chemotherapeutics and eventually leads to therapeutic failure and patient death. Historically, screening for oncology directed compounds has been performed in 2-dimensional monolayer cultures which fail to replicate the complex architecture and microenvironment of tumors in vivo. To address this need using prototype manufactured 384-well round bottom clear black plates coated with hydrogel (commonly referred to as ultra-low attachment or ULA plates) we have developed a method to generate single cell type spheroids to accommodate their use in high throughput screening. These cultures were systematically compared to spheres grown in conventional plates and comparative imaging analyses were carried out to assess sphere formation. In addition, using the same plates, we have developed multicellular tumor spheroids (MCTS) composed of various cell types cultured in the same well. Differences in the cellular compositions of these spheroids in response to drugs can be quantified using high content imagers such as the WiScan from Idea-Bio and the High Throughput Flow Cytometer from IntelliCyt. These heterotypic, differentially labeled spheroids are a valuable asset in the generation of cell-based HTS assays capable of identifying molecules that selectively kill TICs and the cells comprising their microenvironment.
  • Corning® TransportoCells™: Overview of a Novel SLC Transporter Model Recorded: Nov 14 2013 49 mins
    During the past decade, the significant role of transporters in drug disposition and safety has been strengthened due to the increasing evidence of transporter mediated drug-drug interaction (DDI). Regulatory agencies recommend evaluating specific drug transporters of emerging importance in drug development. Appropriate in vitro characterization of drug interactions with these transporters facilitates decision-making and development of appropriate clinical plans in drug development. Corning Life Sciences have recently developed a novel SLC transporter model to help the pharmaceutical industry address regulatory guidance in a fast and easy manner. In this webinar, we will provide an overview of the product validation and applications for the recently launched TransportoCells™ cryopreserved SLC transporter model.
  • Overview of In Vitro ABC Transporter Models and Applications Recorded: Oct 29 2013 64 mins
    During the past decade, increasing clinical evidence of transporter mediated drug-drug interaction (DDI) has highlighted the significant role transporters play in drug disposition and safety. Regulatory authorities recommend evaluating specific drug transporters of emerging importance during drug development, including SLC and ABC transporters. ABC transporters are more challenging to study because they are usually expressed on the apical side of cell membrane (i.e., ATP and substrate binding sites facing inside of the cell), which can limit the direct access of compounds to the transporters in the absence of a relevant uptake transport mechanism. It is critical to utilize an appropriate in vitro system to evaluate drug interactions with these transporters in order to gain better insight into the mechanisms of transporter mediated drug disposition and elimination.

    Corning Life Sciences offers a broad spectrum of in vitro models to support drug transporter studies. This webinar will provide an overview of in vitro ABC transporter models, as well as the pros and cons of each model in deciphering drug ADME features.
  • Cell Culture Contamination Part 3 - Strategies for Reducing Contamination Recorded: Sep 24 2013 56 mins
    In the third part of our three lecture series on cell culture contamination, we will focus on everyday management of cell culture contamination. We will discuss how to reduce cell culture accidents by using good aseptic technique, the importance of freeze stocks, and how to appropriately monitor for contamination. We will also learn how to track down the source of contamination to prevent future accidents.
  • Applications of Corning® FluoroBlok™ Cell Culture Inserts Recorded: Sep 17 2013 48 mins
    In vitro cell migration and invasion assays are frequently used as model systems for studying the directed movement of cells towards a chemoattractant stimulus, or to determine how a particular drug, growth factor or extra cellular matrix coating affects that movement. The classic method used to analyze this movement, the Boyden chamber, can be time-consuming, labor-intensive, and subjective.
    An improved version of this technology was developed, Corning FluoroBlok. As cells migrate or invade through a fluorescence blocking membrane, they are detected using a bottom-reading microplate reader or inverted fluorescence microscope. Cells remaining in the upper chamber of the insert are shielded from detection, allowing for quantitation of cell numbers in this homogeneous assay system.
    Recommended uses of the FluoroBlok system as well as recent improvements will be reviewed in this seminar.
  • Cell Culture Contamination Part 2 - Aseptic Technique Recorded: Jul 17 2013 46 mins
    Studies have shown that at least 20% of the animal cell cultures currently in existence are contaminated by either microorganisms or other cell lines. This three part live, on-line seminar series will review the scope of this major problem, examine some of its causes, and discuss techniques for avoiding contamination. It will also explore some key, simple strategies to monitor for contamination and prevent losses through careful culture management.

    This webinar will specifically focus on aseptic technique: developing a practical approach to aseptic technique; reducing day-to-day contamination problems in the lab; and helpful hints for avoiding contamination.
  • Defined,Animal-free Synthetic Surfaces for Culture of Cells in Clinical Research Recorded: Jun 19 2013 43 mins
    Expansion of stem cells and some primary cells requires either animal-origin components in culture media or coating of the culture vessels with human or animal-derived extracellular matrix (ECM) protein. Growing concerns about introducing human and animal-derived pathogens into the culture necessitate the need for animal- free (xeno-free and human-origin components-free) culture environment. Herein, we present defined and synthetic surfaces for cell culture. Corning® PureCoat™ ECM Mimetic cultureware collagen I peptide and fibronectin peptide support culture of cell types requiring collagen I or fibronectin protein -coated surfaces. Corning Synthemax® surface consists of a vitronectin peptide and supports undifferentiated expansion of human pluripotent stem cells (hPSC) and neural progenitor cells (NPCs). ECM Mimetic and Synthemax cultureware are pre-coated, synthetic, animal-free, and room temperature stable. Synthemax-SC is available for self-coating.

    We demonstrate expansion and functionality of several clinically relevant cell types including hPSCs (human embryonic stem cells and induced pluripotent stem cells), MSCs, human keratinocytes (HKN), endothelial colony forming cells (ECFCs), NPCs and cell lines for bio manufacturing (CHO and Vero) on these surfaces. Corning Synthemax and ECM mimetic cultureware are versatile surfaces compatible with multiple media for culture of various cell types providing a ready to use alternative to ECM coating where animal-free and defined conditions are desirable.
  • Cell Culture Contamination Part 1 – Understanding Cell Culture Contamination Recorded: Jun 11 2013 46 mins
    Recent studies have shown that at least 20% of the animal cell cultures currently in use in the US are contaminated by either microorganisms or other cell lines. This three part live, on-line seminar series will review the scope of this major problem and examine some of its causes and techniques for avoiding it. It will also explore some key, easy to employ strategies for preventing these losses by careful culture management.

    This webinar will discuss good aseptic technique: developing a practical approach to aseptic technique; reducing day-to-day contamination problems in the lab; and helpful hints for avoiding contamination.
  • Tips and Techniques for Enhancing Your Cell Culture Recorded: May 14 2013 61 mins
    Advances in the understanding of the behavior and function of biological systems are dependent on the study of cells and tissues. An essential tool in this research is the use of in vitro cell culture. Many variables contribute to providing a physiological environment for the cell in the laboratory, a few examples include cell source, isolation techniques, growth conditions such as matrix proteins and soluble factors, and cell age. Basic laboratory practices are sometimes overlooked as a source of discrepancy in data; however the application of fastidious and reproducible technique can reduce cell culture as a source of data variation. As specialized techniques have been developed to modulate cells and tissues in vitro, the importance of reproducible data has become paramount. In this presentation, we will identify and discuss basic principles of in vitro mammalian cell culture that influence the quality of experimental results.
  • The Use of In Vitro 3D epithelial Cell Models (MucilAir™) in Drug Development fo Recorded: Apr 24 2013 55 mins
    In recent decades, the nasal and bronchial mucosa has become an established administration site for systemic as well as local drug delivery. For developing novel drugs intended for this route, reliable methods are needed for assessing the rate and extent of absorption across the nasal and bronchial epithelium. Epithelix has developed a novel in vitro cell model of the human airway epithelium named MucilAir™. MucilAir™ maintains the fully differentiated, morphologically and functionally, characteristics of the native tissues for more than one year. Using this system, the typical characteristics of the airway epithelium are observed (e.g. tight junctions, cilia beating, ciliated cells, basal cells, mucous cells, cytokine/chemokine/metalloproteinase release, active ion transport and CypP450s activity). Epithelia from several pathologies can be reconstructed (e.g. Asthma, Allergic Rhinitis, COPD, CF, etc.). Due to its unique long shelf-life, this model is used for studying the human respiratory diseases, and for testing the long-term/chronic effects of drugs candidates on respiratory tract. Several applications of MucilAir™ relevant to drug delivery, inhalation efficacy and toxicity assessment will be presented. For each application, specific examples of in vitro tests will be selected to highlight the Pros and Cons of using in vitro human airway epithelia for development of new drug candidates for respiratory diseases.
  • Overview of In Vitro Methods for Studying Drug Glucuronidation Recorded: Apr 17 2013 59 mins
    Glucuronidation is as a major pathway for the metabolism and elimination of drugs in humans. It is second only to P450 for the metabolic clearance of currently marketed drugs. The glucuronidation reaction is catalyzed by the Phase 2 enzyme UDP-glucuronosyltransferase (UGT), which like the P450s exists as a superfamily of enzymes with broad and overlapping substrate specificities. Identification of the UGT isoforms important for the glucuronidation of new chemical entities is essential for predicting and avoiding the risk of adverse reactions due to either drug-drug interactions or genetic polymorphisms. This webinar will provide an in depth overview of in vitro methods for studying UGT pathways. Important parameters for setting up UGT assays using tissue fractions and recombinant UGT enzymes will be discussed, as well as the methods and tools currently available for conducting UGT reaction phenotyping studies.
  • Evaluation of mRNA and Enzyme Activity Recorded: Mar 13 2013 47 mins
    Recent guidance from the FDA and EMA advocates the use of human hepatocytes as the test system for evaluating cytochrome P450 induction potential. Both agencies indicate that use of hepatocytes that have been prequalified for response to known clinical inducers and non-inducers are acceptable and/or preferred for certain model applications. In addition, the use of mRNA alone is suggested as the necessary endpoint to evaluate induction response (except in cases where enzyme stabilization is suspected as a mechanism). However, the applicability of using prequalified hepatocytes as the test system, and the use of mRNA alone as a response endpoint, has not been widely demonstrated. To this end, we have examined the induction response from a set of 20 compounds, including established clinical inducers and non-inducers of CYP3A4/5, in cryopreserved hepatocytes from three donors. The endpoint examined was CYP3A4 mRNA, typically over 8 concentration points in an effort to enable calculation of EC50 and Emax. Results were used to determine relative induction scores (RIS) and R3 values that may classify a drug candidate as a potential clinical inducer. The results and merits of these and other parameters for evaluating the induction potential of drug candidates will be discussed.
  • Tips and Techniques for Growing Happier Cells Recorded: Feb 19 2013 58 mins
    Culturing and producing healthy cells takes more than good sterile technique. Having a clear understanding of a cell culture’s requirements and history is a must. This knowledge is required to facilitate the development of the necessary conditions that will provide an environment for the cell culture to thrive . This webinar will cover the following topics:
    • What are the conditions which make happy cultures and what can be done to maintain these conditions – tips and techniques
    • Selecting the correct culture environment is critical to growing happy cells
    • Understand the impact of stress on cultures and provide some ideas on to reduce stressful conditions
  • Getting the Most Out of Your Transfection/Transductions Recorded: Jan 29 2013 57 mins
    Transfection and transduction of eukaryotic cells are powerful techniques employed to manipulate and study gene expression. Reports have indicated that the use of viruses for the delivery of transgenes is one of the most commonly used tools in research. Additionally, virus transductions have been recently used at both the preclinical and clinical stages in cell therapy as well as with vaccine production leading to an increase in demand to produce more virus as efficiently as possible. This webinar will focus on Adenovirus and Lentivirus vector production scale up and will include optimizations techniques that may improve viral yields.
  • A mechanistic approach to understanding epithelial barrier function Recorded: Dec 12 2012 62 mins
    Dr. Turner’s research is focused on intestinal epithelial biology, with particular emphasis on tight junction regulation and inflammatory bowel disease. His group takes a multidisciplinary approach that integrates cell biology, transport physiology, electrophysiology, structural biology, molecular biology, and mucosal immunology to define fundamentals of structure and function; understand mechanisms of regulation in vitro and in vivo models; determine the contributions of barrier dysfunction to gastrointestinal disease; understand the role of the epithelial barrier in regulating other mucosal processes, e.g. immune responses; and develop novel means to correct barrier function and restore health.
  • Developing and Optimizing Cell-Based assays using Automation Recorded: Dec 11 2012 61 mins
    In vitro cell-based assays have become a mainstay in many laboratories. The live cell provides a model far superior to that using purified components to build an assay.. Cell-based assays present particular challenges for the experimenter, however, primarily with maintaining cellular responses in microplates that reflect what occurs naturally (i.e. in tissue in a living organism). In this webinar, we will provide helpful advice and insights for setting up and optimizing cell-based assays using automation.

    You will learn:
    • Understanding how cell-based assays benefit from automated liquid handling
    • The importance of choosing the correct microplate, instrumentation and settings to run your cell-based assay.
    • Tools, tips and tricks for optimizing cell-based assays when using liquid handling instrumentation.
  • Cell invasion through extracellular matrix: advantages, tips and uses Recorded: Nov 6 2012 50 mins
    Tumor cells must detach from the primary tumor and invade through extracellular matrix to metastasize. In particular, the cells must attach, degrade, and migrate through the basement membrane matrix underlying blood vessels. A simple, rapid, reliable, flexible, and quantitative in vitro Invasion Assay was developed more than 25 years ago and is widely used today.
    This webinar will cover how the assay is performed, provide some tips for optimal and reproducible results, and discuss various uses of the assay with examples. The emphasis will be on using basement membrane extract (BME) and tumor cells but other matrices and endothelial cells will be mentioned.
Training for Life Science Researchers
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Basic Disinfection Practices for Tissue Culture Laboratories
  • Live at: Feb 2 2012 5:00 pm
  • Presented by: Marian Downing
  • From:
Your email has been sent.
or close
You must be logged in to email this